Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab in Paroxysmal Nocturnal Hemoglobinuria (Single-arm, China)
CTR20230832Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of eculizumab in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Alexion Pharmaceuticals. Started Mar 2023; status: completed.
02
Drugs
eculizumab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on CTR20230832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230832.